Press Releases August 13, 2026 05:00 PM

NovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026

NovaBridge Biosciences to Report First Half 2026 Financial Results and Corporate Update on August 20, 2026

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
NBP

NovaBridge Biosciences announced a webcast scheduled for August 20, 2026, to discuss the company's financial results for the first half ended June 30, 2026, along with recent corporate progress. The biotechnology company focuses on therapeutic programs in oncology and ophthalmology, aiming to advance innovation through a disciplined development and partnering strategy.

NovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026
NBP
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • NovaBridge is set to report H1 2026 financial results in a webcast open globally, highlighting transparency and investor communication.
  • The company focuses on oncology and ophthalmology therapeutic programs, including candidates givastomig and VIS-101, representing targeted innovation within biotech sector.
  • NovaBridge employs a strategy combining development, financing, and partnering to efficiently bring therapies to market, illustrating a sustainable business model in biotechnology.

ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value, today announced that it will hold a webcast on Thursday, August 20, 2026 at 9:00 AM ET/9:00 PM China Standard Time to discuss recent corporate progress and financial results for the first half ended June 30, 2026.

Webcast Information:

  • Date: Thursday, August 20, 2026
  • Time: 9:00 AM ET/9:00 PM China Standard Time
  • Web Access - China: Click here
  • Webcast Access – All other locations: Click here

The live and archived webcast can also be accessed by visiting the NovaBridge Biosciences website on the Upcoming Events section of the Investors page. A replay of the webcast will be archived for at least 30 days after the event.

About NovaBridge

NovaBridge Biosciences (Nasdaq: NBP) is a global biotechnology company advancing a portfolio of therapeutic programs in oncology and ophthalmology.. The Company identifies differentiated therapeutic opportunities, generates value-defining clinical evidence, and applies the development, financing, and partnering strategy best suited to each program.

NovaBridge's portfolio includes programs in oncology and ophthalmology, led by givastomig and VIS-101. The Company's objective is to build a sustainable biotechnology company by repeatedly identifying differentiated innovation, advancing it efficiently, and bringing innovative therapies to patients through the path best suited to each opportunity.

For more information, please visit www.novabridge.com and follow us on LinkedIn.

NovaBridge Investor & Media Contacts

NovaBridge Biosciences
+1-240-745-6330
[email protected]

Bill Begien, VP, Investor Relations
[email protected]

Jessica Zhang, Director, Public Relations
[email protected]


Risks

  • The reliance on advancing clinical programs in oncology and ophthalmology subjects the company to typical biotech risks such as clinical trial failure or regulatory delays, impacting investment outcomes.
  • Financial results might reflect uncertainties in revenue generation or development expenditure, which could affect market confidence.
  • Market conditions affecting financing or partnerships could pose challenges to the company's strategic growth plans.

More from Press Releases

Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress Aug 13, 2026 BIO-key’s Bottom Line Improves 51% on 13% Rise in Q2 Revenues Reflecting Strength with Government, Defense, and Financial Sector Customers Globally; Call Tomorrow at 10am ET Aug 13, 2026 Navient declares third quarter common stock dividend Aug 13, 2026 Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update Aug 13, 2026 Stardust Power Reports Q2 2026 Financial Results and Business Update Aug 13, 2026